An emerging potential therapeutic target for osteoporosis: LncRNA H19/miR-29a-3p axis
Osteoporosis (OP) is a complex systemic disease characterized by a loss of bone density, leading to bone fragility and an increase risk of fractures of the hip, spine and wrist. The clinical therapeutic effect is still far from satisfactory. Thus, further studies are urgently needed to explore the p...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2020-11-01
|
Series: | European Journal of Histochemistry |
Subjects: | |
Online Access: | https://ejh.it/index.php/ejh/article/view/3155 |
id |
doaj-490f60853f2c4cfd836895c4577ab8ca |
---|---|
record_format |
Article |
spelling |
doaj-490f60853f2c4cfd836895c4577ab8ca2020-11-25T04:06:55ZengPAGEPress PublicationsEuropean Journal of Histochemistry 1121-760X2038-83062020-11-0164410.4081/ejh.2020.3155An emerging potential therapeutic target for osteoporosis: LncRNA H19/miR-29a-3p axisZiqi Li0Zhinan Hong1Yuesheng Zheng2Yongwei Dong3Wei He4Yingjia Yuan5Junbiao Guo6Department of Joint Disease, Traumatology and Orthopedics institute of Guangzhou University of Chinese Medicine, the third affiliated hospital of Guangzhou University of Chinese Medicine, GuangzhouDepartment of Joint Disease, Traumatology and Orthopedics institute of Guangzhou University of Chinese Medicine, the third affiliated hospital of Guangzhou University of Chinese Medicine, GuangzhouDepartment of Orthopedics, Jinshazhou hospital of Guangzhou University of Chinese Medicine, GuangzhouDepartment of Orthopedics, Jinshazhou hospital of Guangzhou University of Chinese Medicine, GuangzhouDepartment of Orthopedics, Jinshazhou hospital of Guangzhou University of Chinese Medicine, GuangzhouDepartment of Joint Disease, Traumatology and Orthopedics institute of Guangzhou University of Chinese Medicine, the third affiliated hospital of Guangzhou University of Chinese Medicine, GuangzhouGuangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, GuangzhouOsteoporosis (OP) is a complex systemic disease characterized by a loss of bone density, leading to bone fragility and an increase risk of fractures of the hip, spine and wrist. The clinical therapeutic effect is still far from satisfactory. Thus, further studies are urgently needed to explore the pathogenesis of OP. In this study, our aim is to explore the underlying molecular mechanism of lncRNA H19/miR-29a-3p axis for regulating of inflammation, proliferation and apoptosis in OP. The expression of lncRNA H19 was significantly upregulated in OP samples compared with the health control. Subsequently, we found that miR-29a-3p is the target of lncRNA H19 in OP. Furthermore, the knockdown of lncRNA H19 was validated to promote the expression of pro-inflammatory mediators, repress cell proliferation and inhibit cell apoptosis in vitro. Moreover, the modulating effects of lncRNA-H19 on the expressions of pro-inflammatory mediators, cell proliferation and apoptosis in vitro were diminished after co-transfecting with miR-29a-3p inhibitor and siRNA-H19. Thus, we concluded that lncRNA H19/miR-29a-3p axis was involved in the development of OP. This study might provide a better understanding of OP development and a potential therapeutic target for OP intervention. https://ejh.it/index.php/ejh/article/view/3155Target therapylncRNA H19miR-29a-3posteoporosis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ziqi Li Zhinan Hong Yuesheng Zheng Yongwei Dong Wei He Yingjia Yuan Junbiao Guo |
spellingShingle |
Ziqi Li Zhinan Hong Yuesheng Zheng Yongwei Dong Wei He Yingjia Yuan Junbiao Guo An emerging potential therapeutic target for osteoporosis: LncRNA H19/miR-29a-3p axis European Journal of Histochemistry Target therapy lncRNA H19 miR-29a-3p osteoporosis |
author_facet |
Ziqi Li Zhinan Hong Yuesheng Zheng Yongwei Dong Wei He Yingjia Yuan Junbiao Guo |
author_sort |
Ziqi Li |
title |
An emerging potential therapeutic target for osteoporosis: LncRNA H19/miR-29a-3p axis |
title_short |
An emerging potential therapeutic target for osteoporosis: LncRNA H19/miR-29a-3p axis |
title_full |
An emerging potential therapeutic target for osteoporosis: LncRNA H19/miR-29a-3p axis |
title_fullStr |
An emerging potential therapeutic target for osteoporosis: LncRNA H19/miR-29a-3p axis |
title_full_unstemmed |
An emerging potential therapeutic target for osteoporosis: LncRNA H19/miR-29a-3p axis |
title_sort |
emerging potential therapeutic target for osteoporosis: lncrna h19/mir-29a-3p axis |
publisher |
PAGEPress Publications |
series |
European Journal of Histochemistry |
issn |
1121-760X 2038-8306 |
publishDate |
2020-11-01 |
description |
Osteoporosis (OP) is a complex systemic disease characterized by a loss of bone density, leading to bone fragility and an increase risk of fractures of the hip, spine and wrist. The clinical therapeutic effect is still far from satisfactory. Thus, further studies are urgently needed to explore the pathogenesis of OP. In this study, our aim is to explore the underlying molecular mechanism of lncRNA H19/miR-29a-3p axis for regulating of inflammation, proliferation and apoptosis in OP. The expression of lncRNA H19 was significantly upregulated in OP samples compared with the health control. Subsequently, we found that miR-29a-3p is the target of lncRNA H19 in OP. Furthermore, the knockdown of lncRNA H19 was validated to promote the expression of pro-inflammatory mediators, repress cell proliferation and inhibit cell apoptosis in vitro. Moreover, the modulating effects of lncRNA-H19 on the expressions of pro-inflammatory mediators, cell proliferation and apoptosis in vitro were diminished after co-transfecting with miR-29a-3p inhibitor and siRNA-H19. Thus, we concluded that lncRNA H19/miR-29a-3p axis was involved in the development of OP. This study might provide a better understanding of OP development and a potential therapeutic target for OP intervention.
|
topic |
Target therapy lncRNA H19 miR-29a-3p osteoporosis |
url |
https://ejh.it/index.php/ejh/article/view/3155 |
work_keys_str_mv |
AT ziqili anemergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis AT zhinanhong anemergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis AT yueshengzheng anemergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis AT yongweidong anemergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis AT weihe anemergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis AT yingjiayuan anemergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis AT junbiaoguo anemergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis AT ziqili emergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis AT zhinanhong emergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis AT yueshengzheng emergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis AT yongweidong emergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis AT weihe emergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis AT yingjiayuan emergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis AT junbiaoguo emergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis |
_version_ |
1724430255907667968 |